{
    "Trade/Device Name(s)": [
        "IMMULITE 2500 OM-MA Immunoassay",
        "Immulite 2500 OM-MA",
        "Immulite Tumor Marker Controls"
    ],
    "Submitter Information": "Siemens Medical Solutions Diagnostics",
    "510(k) Number": "K072794",
    "Predicate Device Reference 510(k) Number(s)": [
        "K983391"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTK",
        "JY"
    ],
    "Summary Letter Date": "November 6, 2007",
    "Summary Letter Received Date": "October 1, 2007",
    "Submission Date": "September 27, 2007",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA125 antigen"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "IMMULITE 2500 Automated Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunometric assay",
        "Solid-phase",
        "Two-site"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for IMMULITE 2500 OM-MA Immunoassay for quantitative CA125 measurement in serum to monitor ovarian cancer with IMMULITE 2500 analyzer",
    "Indications for Use Summary": "For in vitro quantitative measurement of CA125 antigen in human serum to aid in monitoring response to therapy and detecting residual ovarian cancer in patients post first-line therapy; Tumor Marker Controls for monitoring assay performance",
    "fda_folder": "Immunology"
}